Cancer Immunology – News and Features

The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.

Research paper describes increase in potency of a GM-CSF-secreting tumor cell immunotherapy by a LAG-3 fusion protein immunopotentiator.

Sixteen patients have completed dosing of CG0070 administered once weekly or once every four weeks at the two lowest of three doses being evaluated.

Select BioSciences’ AMT event held in Barcelona was well attended, with more than 400 participants, around 40 exhibitors and a full two-day programme.

New research has shown that the function of a type of cell that helps modulate immune responses is impaired inside tumors in mice.

The agreement aims at developing and commercializing Cell Genesys' GVAX immunotherapy for prostate cancer.

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.

Two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology.

Idera has agreed to exclusively license the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists.